Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT04706390
Recruiting Observational

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination

NCT04706390 · tracked via the Priya Life Science Norway tracker
Sponsor
University of Bergen
Phase
Observational
Started
2021-01-12
Last updated
2024-04-19

Condition(s) studied

Covid19

Investigational drug(s) / intervention(s)

covid-19 vaccine →

covid-19 vaccine: vaccination

Study summary

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or vaccines available to mitigate the pandemic. Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional marketing authorisation granted by the European Medicines Agency and further vaccine will be licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will recruit subjects who will be prioritised for vaccination with the primary aim of comparing the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2 and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples will be collected to evaluate the complications and kinetics, duration and breadth of the immune responses comparing natural infection to vaccination.

Eligibility

Sex
ALL
Min age
20 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * subjects prioritized by national vaccination program Exclusion Criteria: * Children * unable or unwilling to provide informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Bergen Bergen Norway Recruiting

More University of Bergen trials in Norway

Coronary Artery Plaque Burden in Stable Angina and Non-obstructive Coronary Artery Disease Active, not recruiting
Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease Active, not recruiting
Plaque Burden and Ischemia in MINOCA Recruiting
Virtual Darkness Theraphy for Agitation in Dementia Recruiting
A Brief Intervention for PTSD - BWRT Enrolling by invitation

Other trials for the same condition

The Corona and COVID-19 Study in Telemark and Agder Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04706390 on ClinicalTrials.gov ↗ ← All trials in Norway